Neoliberal technocracy: Explaining how and why the US Food and Drug Administration has championed pharmacogenomics
S Hogarth - Social Science & Medicine, 2015 - Elsevier
By 2004 the FDA had emerged as a champion of pharmacogenomics as an exemplar for
novel approaches to drug development. This was made clear in 2004 when the agency …
novel approaches to drug development. This was made clear in 2004 when the agency …
Neoliberal technocracy: explaining how and why the US Food and Drug Administration has championed pharmacogenomics
S Hogarth - Social science & medicine (1982), 2015 - pubmed.ncbi.nlm.nih.gov
By 2004 the FDA had emerged as a champion of pharmacogenomics as an exemplar for
novel approaches to drug development. This was made clear in 2004 when the agency …
novel approaches to drug development. This was made clear in 2004 when the agency …
[PDF][PDF] Neoliberal technocracy: Explaining how and why the US Food and Drug Administration has championed pharmacogenomics
S Hogarth - Social Science & Medicine, 2015 - academia.edu
abstract By 2004 the FDA had emerged as a champion of pharmacogenomics as an
exemplar for novel approaches to drug development. This was made clear in 2004 when the …
exemplar for novel approaches to drug development. This was made clear in 2004 when the …
Neoliberal technocracy: Explaining how and why the US Food and Drug Administration has championed pharmacogenomics
S Hogarth - Social Science & Medicine, 2015 - econpapers.repec.org
By 2004 the FDA had emerged as a champion of pharmacogenomics as an exemplar for
novel approaches to drug development. This was made clear in 2004 when the agency …
novel approaches to drug development. This was made clear in 2004 when the agency …
Neoliberal technocracy: Explaining how and why the US Food and Drug Administration has championed pharmacogenomics
S Hogarth - Social Science & Medicine, 2015 - ideas.repec.org
By 2004 the FDA had emerged as a champion of pharmacogenomics as an exemplar for
novel approaches to drug development. This was made clear in 2004 when the agency …
novel approaches to drug development. This was made clear in 2004 when the agency …
Neoliberal technocracy: Explaining how and why the US Food and Drug Administration has championed pharmacogenomics
S Hogarth - Social Science & Medicine, 2015 - infona.pl
By 2004 the FDA had emerged as a champion of pharmacogenomics as an exemplar for
novel approaches to drug development. This was made clear in 2004 when the agency …
novel approaches to drug development. This was made clear in 2004 when the agency …
Neoliberal technocracy: Explaining how and why the US Food and Drug Administration has championed pharmacogenomics
S Hogarth - Social Science and Medicine, 2015 - kclpure.kcl.ac.uk
By 2004 the FDA had emerged as a champion of pharmacogenomics as an exemplar for
novel approaches to drug development. This was made clear in 2004 when the agency …
novel approaches to drug development. This was made clear in 2004 when the agency …
Neoliberal technocracy: explaining how and why the US Food and Drug Administration has championed pharmacogenomics.
S Hogarth - Social Science & Medicine (1982), 2015 - europepmc.org
By 2004 the FDA had emerged as a champion of pharmacogenomics as an exemplar for
novel approaches to drug development. This was made clear in 2004 when the agency …
novel approaches to drug development. This was made clear in 2004 when the agency …